Can't make it to Longwood on September 12? Join us in Cambridge for two exciting talks on I-O!
Understanding immuno-microenvironment in HPV+ JRRP: the role of Tregs and B cells in disease progression and disease control
Tingyu Liu, PhD, Postdoctoral Fellow Novartis Institute of Biomedical Research
Juvenile respiratory recurrent papillomatosis (JRRP) is a disease related to infection of HPV subtype 6 or 11 and primarily affects children and adolescents with a median age of diagnosis of 3.8 years. In a study including 9 patients, we found tumor-infiltrating T cells had high expression of co-inhibitory receptor programmed death 1 (PD-1) and some tumors showed expression of PD-1 ligand PD-L1. Relative to patient-matched peripheral blood mononuclear cells (PBMCs), tumor-infiltrating T cells produced higher or similar levels of IL-2, IFN-γ and TNF-α. Emerging data suggests a role for regulatory T cells and B cells in promoting and controlling of tumors respectively. Collectively, these data suggest that activated immune cells are recruited to the tumor in JRRP patients and that further investigation may uncover potential pathways for therapeutic intervention.
To learn more about Tingyu, click here.
We are what we eat: Impact of metabolic environment on T cell differentiation, function, and fate
Pei-Yi Lin, PhD, Manager R&D Cellular Medicines Cell Culture & Cell Therapy, Thermo Fisher Scientific Grand Island, NY
The pathways that govern naiÅNve T cell fate towards an antitumor effector T cell are complicated and influenced by a variety of factors such as cytokines and metabolic environment. Recent advances in the field of immunometabolism support the concept that fundamental processes in T cell biology, such as TCR-mediated activation and T helper cell differentiation, are closely linked to changes in the metabolic environment. Manipulation of metabolic networks may provide new strategies to promote subsets of T cells that are responsible for cancer regression in patients. This talk will discuss the latest findings in the field and novel approaches to enrich for ‘metabolically fit’ T cells that can sustain anti-tumor responses.